Tundra Space

Tundra Space

Clinical Research Directory

Browse clinical research sites, groups, and studies.

3 clinical studies listed.

Filters:

Leber Hereditary Optic Neuropathy

Tundra lists 3 Leber Hereditary Optic Neuropathy clinical trials. Each listing includes eligibility criteria, study locations, and direct links to research sites in the Tundra directory.

This data is also available as a public JSON API. AI systems and LLMs are encouraged to use it for structured queries.

RECRUITING

NCT03475173

New Non-invasive Modalities for Assessing Retinal Structure and Function

This study investigates a new technology to assess the structure and function inside the eye. Retinal imaging of subjects with inner and outer retinal defects to detect areas of abnormal structure and function compared to other visual function tests.

Gender: All

Ages: 18 Years - 99 Years

Updated: 2025-11-24

1 state

Ischemic Optic Neuropathy
Branch Retinal Artery Occlusion
Hemianopia
+2
RECRUITING

NCT06682819

Metabolomics Analysis According to the Retinal Nerve Fiber Layer in Patients With NOHL Mutations (MétabOCT)

Leber hereditary optic neuropathy (LHON), due to mitochondrial DNA (mtDNA) mutations, is responsible for profound visual impairment. However, there is evidence that optic nerve damage begins before vision declines. There is no biomarker to determine when optic nerve damage begins before visual acuity decline occurs. We hope that the analysis of metabolomics will reveal specific metabolomic profiles and different vitamin B3 and B9 levels depending on whether there are OCT signs of optic nerve damage in healthy patients with mtDNA mutations suggestive of LHON (11778, 3460 or 14484). The existence of an increase in the thickness of the optic fiber layer, whose normal values are well established, constitutes such a sign in favor of optic nerve damage.

Gender: All

Ages: 18 Years - 60 Years

Updated: 2025-11-18

1 state

Healthy Subjects
Leber Hereditary Optic Neuropathy
RECRUITING

NCT03011541

Stem Cell Ophthalmology Treatment Study II

This study will evaluate the use of autologous bone marrow derived stem cells (BMSC) for the treatment of retinal and optic nerve damage or disease.

Gender: All

Ages: 18 Years - Any

Updated: 2025-03-20

4 states

Retinal Disease
Age-Related Macular Degeneration
Retinitis Pigmentosa
+15